Supplementary Table 1. Result of multiregion sequencing (targeted amplicon sequencing).

	Main tumor (B)	HGD in MPD (B)	HGD (C)	LGD in MPD (D)	LGD (E)	LGD (F)	ADM (F)	LGD (G)
KRAS	G12V (10.3 %) 1	G12V (11.5 %) 1	G12V (19.2 %) 1	G12V (1 %) 1	G12V (2 %) 1	G12D (5.2 %) 1	G12D (2 %) 1	G12D (1 %) 1
TP53	WT	WT	WT	WT	WT	WT	WT	WT
CDKN2A	WT	WT	WT	WT	WT	WT	WT	WT
SMAD4	WT	WT	WT	WT	WT	WT	WT	WT
GNAS	WT	WT	WT	WT	WT	WT	WT	WT
RNF43	WT	WT	WT	WT	WT	WT	WT	WT
BRAF	WT	WT	WT	WT	WT	WT	WT	WT
PIK3CA	WT	WT	WT	WT	WT	WT	WT	WT
STK11	WT	WT	WT	WT	WT	WT	WT	WT
IDH1	WT	WT	WT	WT	WT	WT	WT	WT
CTNNB1	WT	WT	WT	WT	WT	WT	WT	WT
MAP2K4	WT	WT	WT	WT	WT	WT	WT	WT
TGFBR1	WT	WT	WT	WT	WT	WT	WT	WT
TGFBR2	WT	WT	WT	WT	WT	WT	WT	WT
ARID1A	WT	WT	WT	WT	WT	WT	WT	WT
SF3B1	WT	WT	WT	WT	WT	WT	WT	WT
RBM10	WT	WT	WT	WT	WT	WT	WT	WT
KDM6A	WT	WT	WT	WT	WT	WT	WT	WT

LGD, low grade dysplasia; HGD, high grade dysplasia; ADM, acinar-to-ductal metaplasia; WT, wild-type.

¹ Values in parentheses indicate the multiregions shown in Fig. 3 .